Solutions
Life Science

AavantiBio is a biopharmaceutical company committed to developing and commercializing novel gene transfer and gene editing therapies for the treatment of rare and ultra-rare genetic diseases. The company is rapidly building a diverse portfolio of gene transfer and gene editing therapies to target debilitating genetic diseases for which the unmet medical need is high for which there are typically no approved therapies treating the underlying disease.

Adagio is developing broadly-neutralizing monoclonal antibodies for the treatment of COVID-19 and other coronavirus infections. The company was created in July 2020 as a spin out of Adimab, a leading antibody discovery company that has discovered and optimized over 40 antibodies that have been progressed into clinical trials by its industry partners. Adagio’s antibodies have been designed to target SARS-CoV-2, the virus that causes COVID-19, in a way that provides potent anti-viral activity against all known forms of the virus. ADG20, the company’s lead asset, is an intramuscular injection that is being developed both as a treatment for COVID-19, as well as a preventive therapy after exposure to SARS-CoV-2. We believe that Adagio will generate a pipeline of broadly-neutralizing antibodies capable of treating future pandemic coronaviruses.

Amylyx Pharmaceuticals, Inc. is a pharmaceutical company working on developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimer's disease and other neurodegenerative diseases.

Annexon (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the brain, body and eye. The company's pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q, the initiating molecule of the classical complement pathway. Annexon is deploying a disciplined, biomarker-driven development strategy designed to establish that its product candidates are engaging the target at a well-tolerated therapeutic dose in the intended tissue compartments.

Aptinyx (Nasdaq: APTX) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate—rather than block or over-activate—NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, or immuno-dermatology. The company is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. Arcutis’ robust pipeline includes four novel drug candidates currently in development for a range of inflammatory dermatological conditions. The company’s lead product candidate, topical roflumilast, has the potential to revitalize the standard of care for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis.

Areteia Therapeutics is a clinical-stage biopharmaceutical company, focused on developing novel therapeutics for respiratory diseases.

Atea Pharmaceuticals is a clinical stage biopharmaceutical company engaged in discovering and developing therapies to address the unmet medical needs of patients with severe viral diseases. Atea’s lead programs are focused on the development of orally- administered direct acting antivirals for the treatment of patients with COVID-19 in the hospital and community settings, the treatment of patients with chronic hepatitis C infection, the treatment of patients with dengue, and the treatment of high-risk patients with severe respiratory syncytial virus infection. Atea’s medicinal chemistry, virology, and pharmacology expertise, bolstered by their collective experience in drug development, enables them to pioneer new advancements in antiviral science. Leveraging the power of their purine nucleotide prodrug platform, their goal is to rapidly advance novel drug candidates with optimal therapeutic profiles for RNA virus targets.

Developer of targeted oncology drugs with a broad oncology pipeline, including two leading assets focusing on lung cancer treatment and GBM.

C4 Therapeutics (Nasdaq: CCCC) is a biopharmaceutical company focused on harnessing the body's natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity.

Cardurion is a clinical-stage biopharmaceutical company developing new therapeutics for the treatment of heart failure and cardiovascular diseases.

Cerevel Therapeutics (Nasdaq: CERE) relentlessly finds paths through complexity to bring real progress and new treatment options to people living with a broad range of neurological and neuropsychiatric disorders.

Cerevel is developing its most advanced therapeutic candidate, tavapadon, for the treatment of both early- and late-stage Parkinson’s disease. Tavapadon was rationally designed as an orally-bioavailable, once-daily partial agonist that selectively targets dopamine D1/D5 receptor subtypes with the goal of balancing meaningful motor activity with a favorable tolerability profile. Cerevel's second most advanced therapeutic candidate, CVL-865, is being developed for the treatment of both epilepsy and anxiety. CVL-865 was rationally designed as an orally-bioavailable, twice-daily positive allosteric modulator that selectively targets GABAA receptors containing alpha-2/3/5 subunits. Cerevel is also developing CVL-231 for the treatment of psychosis. CVL-231 was rationally designed as a positive allosteric modulator that selectively targets the muscarinic acetylcholine 4 receptor (M4) subtype to harness the anti-psychotic benefit believed to be associated with M4 while minimizing the side effects typically associated with pan-muscarinic agonists.

Cerevel Therapeutics was founded in 2018 as a partnership between Bain Capital Life Sciences, Bain Capital Private Equity, and Pfizer to build a new, fully-integrated biopharmaceutical company focused on advancing a broad portfolio of medicines for central nervous system disorders. Both Bain Capital Life Sciences and Bain Capital Private Equity are represented on the Company's Board of Directors.

Dynavax Technologies (Nasdaq: DVAX) is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis, and universal influenza.

Emalex is developing a novel investigational compound that is being studied as a potential treatment for certain central nervous system disorders such as Tourette’s Syndrome and Restless Legs Syndrome with Augmentation (RLSa).

EQRx is a Cambridge-based company that aims to disrupt the traditional innovation and pricing model of biopharma by developing and commercializing less expensive, branded medications that are equally good or better than the market leader(s). EQRx intends to achieve innovator-type operating margins at a radically lower price point. EQRx believes it can deliver on this vision by developing deep partnerships with US and ex-US payers who are highly incentivized by price to shift market share to EQRx, thus substantially reducing the need for sales and marketing infrastructure, and meaningfully streamlining R&D costs. EQRx is a purpose-built disruptor at scale, remaking medicine to bend the cost curve in drug pricing.

Freenome is a biotechnology company that has pioneered a comprehensive multiomics platform for early cancer detection with a routine blood draw, beginning with a colorectal cancer screening test. The Company combines its deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating cell-free biomarkers. Freenome is integrating the actionable insights through a machine learning feedback loop with healthcare providers to leverage real-world data and improve patient care through early detection.

Gynesonics is a women's healthcare company focused on minimally invasive, incision-free, uterus-preserving, transcervical technologies for diagnostic and therapeutic applications. Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.

Hugel (KOSDAQ: 145020) is a publicly traded biopharmaceutical company in Korea that primarily focuses on the manufacturing and selling of botulinum toxin (BTX – widely known as Botox) and hyaluronic acid dermal fillers (HA Fillers).

Imperative Care is speeding new answers to stroke by developing a portfolio of innovative solutions to address the vast and urgent unmet needs in stroke care. The Company is singularly dedicated to improving the way stroke is treated by advancing medical technology, equipping healthcare providers to evolve best practices and elevate the standard of care for stroke patients.

Interius BioTherapeutics is a preclinical stage gene therapy company developing novel methods for in vivo cell-specific gene delivery, creating a breakthrough platform with multi-product potential. The company was founded based on inventions from the laboratory of Dr. Saar Gill, a leading physician-scientist in the fields of cell and gene therapy at the Center for Cellular Immunotherapies at the University of Pennsylvania.

JenaValve Technology develops and manufactures transcatheter aortic valve replacement (TAVR) systems to treat patients suffering from aortic valve disease. The Company is in late-stage clinical development of its next-generation transfemoral TAVR system in both the U.S. and CE mark countries for treating patients with severe aortic regurgitation or aortic stenosis.

Jnana scientists are unlocking the full potential of chemoproteomics to uncover unique binding sites on highly validated protein targets and accelerate the discovery of new molecules that can change the course of disease.

Kestra is a development-stage manufacturer of wearable cardioverter defibrillator solutions designed to prevent sudden cardiac death and promote cardiac recovery in at-risk patients.

Marinus Pharmaceuticals (Nasdaq: MRNS) is dedicated to the development of innovative therapeutics to treat rare seizure disorders. Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, anti-depressant and anti-anxiety effects. Ganaxolone is being developed in IV and oral dose formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings.

Mersana Therapeutics (Nasdaq: MRSN) is a clinical-stage biopharmaceutical company using its differentiated and proprietary antibody-drug conjugate platforms to rapidly develop novel antibody-drug conjugates with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second antibody-drug conjugate product candidate targeting NaPi2b-expressing tumors is in the dose escalation portion of a Phase 1 proof-of-concept clinical study.

Nautilus Biotechnology seeks to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. By integrating breakthrough innovations in computer science, engineering, and biochemistry, Nautilus has designed a large-scale, single molecule proteomic analysis technology capable of delivering extreme sensitivity and scale. By enabling an expansion of both the depth and breadth of proteomic studies, Nautilus’ technology has the potential to revolutionize how biological research is conducted, drugs are identified and developed, and human disease is treated.

New Amsterdam is developing transformative, clinically validated oral therapies for patients with metabolic diseases.

Nuvalent, Inc. is creating precisely targeted therapies designed to overcome the limitations of existing therapies for clinically proven kinase targets for patients with cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses.